| Patient | Rabindranath Tagore |
|---|---|
| Date of birth | 1946-05-07 |
| Identifiers | MRN HR-ET021-SYN; SSN (made up) 000-21-9325 |
| Document date | 2026-11-01 |
| Author | Arvind Sengupta, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New-patient visit for a weak stream, straining, and frequent urination at night, with a feeling that the bladder does not empty. Concerns: A weak stream, straining, dribbling, and getting up four times a night for months; lately he passes only small amounts and feels his bladder never empties; Since a severe urinary infection in the hills five months ago he has not felt well; he wants to keep writing and teaching; He fears an operation more than he fears his illness, and wants to know every gentler choice before any surgery is decided. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Tamsulosin 0.4 mg oral capsule, one capsule by mouth at bedtime | One capsule by mouth 30 minutes after the evening meal, at bedtime | Oral route | 2026-02-17 | active | S |
| Finasteride 5 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-03 | active | S |
| Polyethylene glycol 3350, 17 g in water once daily as needed for constipation | 17 g dissolved in a glass of water once daily if no bowel movement for two days | Oral route | 2026-02-17 | active | S |
| Ceftriaxone 1 g intramuscularly, one dose in clinic | One dose of 1 g intramuscularly after cultures | Intramuscular route | 2026-03-17 to 2026-03-17 | completed | S |
| Cefpodoxime 200 mg oral tablet, one tablet by mouth twice daily for 6 days | One tablet by mouth twice daily with food, to complete 7 days of treatment | Oral route | 2026-03-17 to 2026-03-23 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for fever or discomfort | Two tablets every 6 hours as needed; no more than 3 g a day | Oral route | 2026-03-17 to 2026-03-23 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Indwelling urethral catheter inserted (16 French, 10 mL balloon) with a leg bag and night bag; 680 mL drained; observed for two hours for post-obstructive diuresis, which did not occur | 2026-02-17 to 2026-02-17 | completed | S |
| Ultrasound of both kidneys and the bladder: no hydronephrosis; kidneys normal in size; bladder wall trabeculated, catheter balloon in place; prostate about 85 mL with a modest median lobe | 2026-03-03 to 2026-03-03 | completed | S |
| Change of urethral catheter before cultures for a febrile catheter-associated infection; urine culture taken from the new catheter | 2026-03-17 to 2026-03-17 | completed | S |
| Trial without catheter after six weeks of tamsulosin: catheter removed in the early morning; voided small amounts; bladder scan 420 mL; catheter replaced | 2026-03-31 to 2026-03-31 | completed | S |
| Second trial without catheter after four months of finasteride with tamsulosin: catheter removed in the early morning; voided 240 mL and 210 mL; bladder scan 150 mL; catheter left out | 2026-07-14 to 2026-07-14 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2025-10-14 | High-dose influenza vaccine, 2025-2026 season | completed | S |
| 2026-06-09 | Respiratory syncytial virus vaccine (adjuvanted), single dose | completed | S |
| 2026-06-09 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2026-06-09 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| Late 1937 | Loss of consciousness, comatose and near death for a time; the illness is not characterized further in the cited source | D (CLM-0005) |
| 15 September 1940 | Severe lower abdominal pain with a severe urinary tract infection while visiting the hills at Kalimpong; brought back unconscious to Calcutta for treatment | D (CLM-0006) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| natural daughter | Tuberculosis in young adulthood; died before him (cause of death not recorded in the cited source) | D (CLM-0016) |
| Concern | Status | Evidence |
|---|---|---|
| A weak stream, straining, dribbling, and getting up four times a night for months; lately he passes only small amounts and feels his bladder never empties | active | S |
| Since a severe urinary infection in the hills five months ago he has not felt well; he wants to keep writing and teaching | active | S |
| He fears an operation more than he fears his illness, and wants to know every gentler choice before any surgery is decided | active | S |
Most recent measures: Symptom score [AUASI] 13 on 2026-07-14; If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that [IPSS] 3 on 2026-07-14; US Urinary bladder Volume post void 150 on 2026-07-14; Leukocytes [#/area] in Urine sediment by Microscopy high power field 60 on 2026-03-17; Hemoglobin [Mass/volume] in Blood 13.4 on 2026-03-17; Sodium [Moles/volume] in Serum or Plasma 140 on 2026-07-14; Potassium [Moles/volume] in Serum or Plasma 4.5 on 2026-07-14; Carbon dioxide, total [Moles/volume] in Serum or Plasma 25 on 2026-07-14; Urea nitrogen [Mass/volume] in Serum or Plasma 18 on 2026-07-14; Creatinine [Mass/volume] in Serum or Plasma 1.12 on 2026-07-14; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 66 on 2026-07-14; Glucose [Mass/volume] in Serum or Plasma 93 on 2026-07-14; Prostate specific Ag [Mass/volume] in Serum or Plasma 2.6 on 2026-07-14; Prostate Volume by derived from height, width and length (US) 85 on 2026-03-03; Leukocytes [#/volume] in Blood by Automated count 13.8 on 2026-03-17; Total score [Mini-Cog] 4 on 2026-03-31; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-06-09 [S]
Strengths and supports: Supports: his writing, his students and colleagues, his family and helpers, and a daily practice of prayer and quiet; no firearms in the home [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Benign prostatic hyperplasia with severe lower urinary tract symptoms (IPSS 26) and bladder outlet obstruction: prostate about 85 mL on ultrasound, smooth and benign on examination, PSA 4.9 ng/mL (PSA density 0.06) | active | confirmed | N40.1 | S — Synthetic modern diagnosis linked to the retrospective enlarged-prostate reading of his last illness; the conflicting cancer claim is not adopted. |
| Urinary retention with severe lower urinary tract symptoms (bladder scan 640 mL after voiding) and a raised creatinine, cause under evaluation | resolved | confirmed | R33.9 | S — Synthetic presenting concern at the index visit, superseded by the diagnosis of benign prostatic hyperplasia with chronic retention at the two-week visit. |
| Chronic urinary retention from bladder outlet obstruction, low risk once drained (no hydronephrosis; creatinine normal after drainage), managed with an indwelling urethral catheter | resolved | confirmed | R33.8 | S — Synthetic diagnosis; resolved after a successful second trial without catheter. |
| Catheter-associated urinary tract infection with fever, without sepsis; resolved | resolved | confirmed | T83.511A | S — Synthetic complication of the synthetic catheter at an unscheduled visit; it echoes, without asserting, the urinary infections of his documented last illness. |
| Mild frailty (Clinical Frailty Scale 5): slow gait (Timed Up and Go 15 seconds), needs help with heavy housework and travel; cognition normal (Mini-Cog 4) | active | confirmed | R54 | S — Synthetic geriatric assessment before the surgical decision. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-02-17 | Symptom score [AUASI] | 26 | {score} | S | ||
| 2026-02-17 | If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that [IPSS] | 5 | {score} | S | ||
| 2026-02-17 | US Urinary bladder Volume post void | 640 | mL | <=100 mL | High | S |
| 2026-02-17 | Leukocytes [#/area] in Urine sediment by Microscopy high power field | 3 | /[HPF] | <=5 /[HPF] | Normal | S |
| 2026-02-17 | Hemoglobin [Mass/volume] in Blood | 13.6 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-02-17 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-02-17 | Potassium [Moles/volume] in Serum or Plasma | 4.7 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-02-17 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-02-17 | Urea nitrogen [Mass/volume] in Serum or Plasma | 27 | mg/dL | 8-23 mg/dL | High | S |
| 2026-02-17 | Creatinine [Mass/volume] in Serum or Plasma | 1.42 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 2026-02-17 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 50 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 2026-02-17 | Glucose [Mass/volume] in Serum or Plasma | 97 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-02-17 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 4.9 | ng/mL | Age-specific upper limit 6.5 ng/mL for 70 to 79 years; halve the expected value on finasteride | Normal | S |
| 2026-03-03 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-03 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-03 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 25 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-03-03 | Urea nitrogen [Mass/volume] in Serum or Plasma | 18 | mg/dL | 8-23 mg/dL | Normal | S |
| 2026-03-03 | Creatinine [Mass/volume] in Serum or Plasma | 1.18 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-03-03 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 63 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-03 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-03-03 | Prostate Volume by derived from height, width and length (US) | 85 | mL | <=30 mL | High | S |
| 2026-03-17 | Leukocytes [#/volume] in Blood by Automated count | 13.8 | 10*3/uL | 3.4-9.6 10*3/uL | High | S |
| 2026-03-17 | Hemoglobin [Mass/volume] in Blood | 13.4 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-03-17 | Sodium [Moles/volume] in Serum or Plasma | 136 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-17 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-17 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-03-17 | Urea nitrogen [Mass/volume] in Serum or Plasma | 25 | mg/dL | 8-23 mg/dL | High | S |
| 2026-03-17 | Creatinine [Mass/volume] in Serum or Plasma | 1.31 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-03-17 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 55 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 2026-03-17 | Glucose [Mass/volume] in Serum or Plasma | 112 | mg/dL | 70-99 mg/dL | High | S |
| 2026-03-17 | Leukocytes [#/area] in Urine sediment by Microscopy high power field | 60 | /[HPF] | <=5 /[HPF] | High | S |
| 2026-03-31 | US Urinary bladder Volume post void | 420 | mL | <=100 mL | High | S |
| 2026-03-31 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-31 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-31 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 24 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-03-31 | Urea nitrogen [Mass/volume] in Serum or Plasma | 19 | mg/dL | 8-23 mg/dL | Normal | S |
| 2026-03-31 | Creatinine [Mass/volume] in Serum or Plasma | 1.16 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-03-31 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 64 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-31 | Glucose [Mass/volume] in Serum or Plasma | 95 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-03-31 | Total score [Mini-Cog] | 4 | {score} | S | ||
| 2026-06-09 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-07-14 | US Urinary bladder Volume post void | 150 | mL | <=100 mL | High | S |
| 2026-07-14 | Symptom score [AUASI] | 13 | {score} | S | ||
| 2026-07-14 | If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that [IPSS] | 3 | {score} | S | ||
| 2026-07-14 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-07-14 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-07-14 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 25 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-07-14 | Urea nitrogen [Mass/volume] in Serum or Plasma | 18 | mg/dL | 8-23 mg/dL | Normal | S |
| 2026-07-14 | Creatinine [Mass/volume] in Serum or Plasma | 1.12 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-07-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 66 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-07-14 | Glucose [Mass/volume] in Serum or Plasma | 93 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-07-14 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 2.6 | ng/mL | Age-specific upper limit 6.5 ng/mL for 70 to 79 years; halve the expected value on finasteride | Normal | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-02-17 | Body height | 183 | cm | S |
| 2026-02-17 | Body weight | 66 | kg | S |
| 2026-02-17 | Body mass index (BMI) [Ratio] | 19.7 | kg/m2 | S |
| 2026-02-17 | Systolic blood pressure | 138 | mm[Hg] | S |
| 2026-02-17 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-02-17 | Heart rate | 76 | /min | S |
| 2026-02-17 | Respiratory rate | 16 | /min | S |
| 2026-02-17 | Body temperature | 36.7 | Cel | S |
| 2026-02-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-03-03 | Body height | 183 | cm | S |
| 2026-03-03 | Body weight | 65.8 | kg | S |
| 2026-03-03 | Body mass index (BMI) [Ratio] | 19.6 | kg/m2 | S |
| 2026-03-03 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-03-03 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-03-03 | Heart rate | 72 | /min | S |
| 2026-03-03 | Respiratory rate | 16 | /min | S |
| 2026-03-03 | Body temperature | 36.6 | Cel | S |
| 2026-03-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-03-17 | Body height | 183 | cm | S |
| 2026-03-17 | Body weight | 65.1 | kg | S |
| 2026-03-17 | Body mass index (BMI) [Ratio] | 19.4 | kg/m2 | S |
| 2026-03-17 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-03-17 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-03-17 | Heart rate | 98 | /min | S |
| 2026-03-17 | Respiratory rate | 18 | /min | S |
| 2026-03-17 | Body temperature | 38.4 | Cel | S |
| 2026-03-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| 2026-03-31 | Body height | 183 | cm | S |
| 2026-03-31 | Body weight | 65.3 | kg | S |
| 2026-03-31 | Body mass index (BMI) [Ratio] | 19.5 | kg/m2 | S |
| 2026-03-31 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-03-31 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-03-31 | Heart rate | 74 | /min | S |
| 2026-03-31 | Respiratory rate | 16 | /min | S |
| 2026-03-31 | Body temperature | 36.6 | Cel | S |
| 2026-03-31 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-04-28 | Body height | 183 | cm | S |
| 2026-04-28 | Body weight | 65.6 | kg | S |
| 2026-04-28 | Body mass index (BMI) [Ratio] | 19.6 | kg/m2 | S |
| 2026-04-28 | Systolic blood pressure | 130 | mm[Hg] | S |
| 2026-04-28 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-04-28 | Heart rate | 72 | /min | S |
| 2026-04-28 | Respiratory rate | 16 | /min | S |
| 2026-04-28 | Body temperature | 36.6 | Cel | S |
| 2026-04-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-06-09 | Body height | 183 | cm | S |
| 2026-06-09 | Body weight | 66 | kg | S |
| 2026-06-09 | Body mass index (BMI) [Ratio] | 19.7 | kg/m2 | S |
| 2026-06-09 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-06-09 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-06-09 | Heart rate | 70 | /min | S |
| 2026-06-09 | Respiratory rate | 16 | /min | S |
| 2026-06-09 | Body temperature | 36.7 | Cel | S |
| 2026-06-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-07-14 | Body height | 183 | cm | S |
| 2026-07-14 | Body weight | 66.2 | kg | S |
| 2026-07-14 | Body mass index (BMI) [Ratio] | 19.8 | kg/m2 | S |
| 2026-07-14 | Systolic blood pressure | 130 | mm[Hg] | S |
| 2026-07-14 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-07-14 | Heart rate | 70 | /min | S |
| 2026-07-14 | Respiratory rate | 16 | /min | S |
| 2026-07-14 | Body temperature | 36.6 | Cel | S |
| 2026-07-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-02-17 | New-patient visit for a weak stream, straining, and frequent urination at night, with a feeling that the bladder does not empty | finished | S |
| 2026-03-03 | Two-week review with kidney and bladder ultrasound results and urology consultation | finished | S |
| 2026-03-31 | Six-week review with a trial without catheter and a geriatric assessment | finished | S |
| 2026-04-28 | Ten-week review: shared decision about treatment and goals of care | finished | S |
| 2026-07-14 | Five-month review with a planned second trial without catheter | finished | S |
| 2026-03-17 | Same-day sick visit for fever with a urinary catheter | finished | S |
| 2026-06-09 | Subsequent annual wellness visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Evaluation: IPSS with the quality-of-life question, bladder scan for post-void residual, urinalysis and urine culture, blood count, creatinine and electrolytes, digital rectal examination, and a kidney and bladder ultrasound for obstruction; a frequency-volume chart once voiding | completed | GL-AUA-BPH-2021, GL-AUA-CUR-2017, GL-CMID-2026 | S |
| PSA only after shared decision-making: it helps estimate prostate size and choose treatment; screening for prostate cancer is not recommended at his age, and he would not want treatment for a slow-growing cancer; drawn before the catheter is placed, because retention and catheters raise it | completed | GL-AUA-BPH-2021, GL-USPSTF-PROSTATE-2018, GL-CMID-2026 | S |
| Indwelling urethral catheter to drain the bladder, with a closed drainage system, the bag below the bladder, daily washing with soap and water, no routine antibiotics or bladder washouts, no treatment of bacteria in the urine without symptoms, a change every four weeks, and same-day review for fever, pain, blood, or a blocked catheter | completed | GL-IDSA-CAUTI-2009, GL-AUA-CUR-2017 | S |
| Tamsulosin 0.4 mg at bedtime for at least three days and usually several weeks before a trial without catheter; fall precautions: take it after the evening meal, rise slowly, sit to pass urine at night, and use a night light | completed | GL-AUA-BPH-2021, GL-BEERS-2023 | S |
| Urology consultation for chronic urinary retention with a raised creatinine: confirm the cause, judge the risk, plan the trial without catheter, advise on a 5-alpha-reductase inhibitor, and set out the procedures that suit a frail 79-year-old who wants to avoid an operation | completed | GL-AUA-BPH-2021, GL-AUA-BPH-2023, GL-CMID-2026, GL-AUA-CUR-2017 | S |
| Medication review with the AGS Beers Criteria: avoid anticholinergic drugs for bladder symptoms while in retention, first-generation antihistamines, and benzodiazepines; avoid nonselective alpha-blockers; review his herbal preparation with the pharmacist for interactions and unlabeled ingredients | completed | GL-BEERS-2023, GL-AYUR-METALS-2008 | S |
| Monitor on the CMID and AUA schedule: IPSS at every visit once voiding; post-void residual with each trial without catheter and after it; creatinine with retention; PSA at baseline and six months after starting finasteride, doubled for interpretation; response to tamsulosin at four to twelve weeks and to finasteride at three to six months | completed | GL-AUA-BPH-2021, GL-AUA-BPH-2023, GL-CMID-2026 | S |
| Geriatric assessment before any surgical decision: frailty, gait and falls, orthostatic blood pressure on tamsulosin, cognition, mood, delirium risk, nutrition, and what matters most to him | completed | GL-BEERS-2023, GL-AUA-BPH-2021 | S |
| Finasteride 5 mg daily for the 85 mL prostate, with a new PSA baseline after six months (measured value doubled for interpretation); trial without catheter after about six weeks of tamsulosin, once any infection is treated | completed | GL-AUA-BPH-2021, GL-AUA-BPH-2023, GL-CMID-2026 | S |
| Surgical options counseled after the failed trial without catheter: laser enucleation (HoLEP) recommended for an 85 mL prostate with refractory retention; transurethral resection and simple prostatectomy as alternatives; prostatic artery embolization under local anesthesia as a less invasive option with less durable results; prostatic urethral lift and water vapor therapy less suitable for this size, median lobe, and retention; each weighed against his frailty, delirium risk, and wishes | completed | GL-AUA-BPH-2021, GL-AUA-BPH-2023, GL-CMID-2026, GL-BEERS-2023 | S |
| His decision, in his own terms: defer any operation or procedure; keep the catheter, changed every four weeks, with tamsulosin and finasteride; a second trial without catheter after three to four months of finasteride; reconsider prostatic artery embolization, then laser enucleation, if that fails or if infections recur, bleeding, stones, or kidney harm develop; continue his herbal preparation after the pharmacist's review | completed | GL-AUA-BPH-2021, GL-AUA-BPH-2023, GL-CMID-2026, GL-AUA-CUR-2017 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Bladder drained and kidney function back to normal within two weeks | 2026-03-03 | completed | Creatinine 1.42 mg/dL at presentation, 1.18 mg/dL after two weeks of drainage; no hydronephrosis | S |
| No catheter-associated infection, or prompt treatment if one occurs | 2026-03-31 | completed | One febrile catheter-associated infection at four weeks, treated in clinic for 7 days without admission; resolved | S |
| A treatment decision that he understands and that fits his values, after a geriatric assessment, by about ten weeks | 2026-04-28 | completed | Chose to continue the catheter with tamsulosin and finasteride and to try again without the catheter after three to four months, deferring surgery; recorded in his own words | S |
| Voiding without a catheter, with a post-void residual under 300 mL, by about five months | 2026-07-14 | completed | Second trial without catheter succeeded: residual 150 mL, IPSS 13 | S |
| Goals of care and a health care agent recorded | 2026-06-09 | completed | Goals of care discussed at the ten-week visit; health care agent named and his wishes recorded at the wellness visit | S |